The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.
An in-office intravitreal therapy delivering a gene for aflibercept expression continues to demonstrate encouraging safety, tolerability, and efficacy in a phase 1 study of patients with neovascular age-related macular degeneration who require frequent injections to control their disease.
Immediate administration after radiation therapy is key.
Patient enrollment for the NORSE 2 clinical trial has been completed, with safety and efficacy data expected to be reported in the third quarter of 2021.
Use of anxiety-screening questionnaires in patients needing intravitreal anti-VEGF injections may help to identify individuals at risk for elevated pain during the procedure, according to research presented at ARVO 2020.
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process
David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.
